iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. (ITOS): 19 pipeline candidates · ~36 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
35.6 months
D/E 0.26 · 14% dilution
Lead: Phase 3
19 candidates
N/A
N/A
A transparent, data-derived signal for iTeos Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$208.1M
Quarterly Burn
$42.4M
Runway
35.6 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (19 candidates)
| Drug | Phase |
|---|---|
| Anti-PD-1 monoclonal antibody | Phase 1 |
| Anticancer agent | Phase 1 |
| Belrestotug | Phase 3 |
| belrestotug (EOS-448/GSK4428859A) | Phase 3 |
| Cobolimab | Phase 1 |
| Dostarlimab | Phase 3 |
| EOS-215 | Phase 1 |
| EOS-448 | Phase 2 |
| EOS-984 | Phase 1 |
| EOS006215 | Phase 1 |
Showing 10 of 19 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in iTeos Therapeutics, Inc.'s pipeline?
iTeos Therapeutics, Inc. (ITOS) has 19 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is iTeos Therapeutics, Inc.'s lead drug candidate?
iTeos Therapeutics, Inc.'s most advanced tracked candidate is Anti-PD-1 monoclonal antibody (Phase 1) for Advanced Solid Tumors.
What is iTeos Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, iTeos Therapeutics, Inc. has approximately 35.6 months of cash runway.
Who is the CEO of iTeos Therapeutics, Inc.?
Chief Executive Officer is the chief executive officer of iTeos Therapeutics, Inc. (ITOS).
Get the full picture on iTeos Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.